These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 18936398)

  • 1. Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling.
    Somani AK; Swick AR; Cooper KD; McCormick TS
    Arch Dermatol; 2008 Oct; 144(10):1341-9. PubMed ID: 18936398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
    Lugaresi A; Durastanti V; Gasperini C; Lai M; Pozzilli C; Orefice G; Sotgiu S; Pucci E; Ardito B; Millefiorini E;
    Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Interferons beta in patients with multiple sclerosis].
    Vlasov IaV; Kuznetsova NI; Poverennova IE; Khivintseva EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(7):54-5. PubMed ID: 16117149
    [No Abstract]   [Full Text] [Related]  

  • 4. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis.
    Greenberg SA; Pinkus JL; Pinkus GS; Burleson T; Sanoudou D; Tawil R; Barohn RJ; Saperstein DS; Briemberg HR; Ericsson M; Park P; Amato AA
    Ann Neurol; 2005 May; 57(5):664-78. PubMed ID: 15852401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production.
    Hedegaard CJ; Sellebjerg F; Krakauer M; Hesse D; Bendtzen K; Nielsen CH
    Mult Scler; 2011 May; 17(5):567-77. PubMed ID: 21177756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-beta-1b.
    Iarlori C; Reale M; Lugaresi A; De Luca G; Bonanni L; Di Iorio A; Feliciani C; Conti P; Gambi D
    J Neuroimmunol; 2000 Jul; 107(1):100-7. PubMed ID: 10808056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS.
    Goertsches RH; Hecker M; Koczan D; Serrano-Fernandez P; Moeller S; Thiesen HJ; Zettl UK
    Pharmacogenomics; 2010 Feb; 11(2):147-61. PubMed ID: 20136355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of interferon-beta on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-beta treatment in patients with multiple sclerosis.
    Wiesemann E; Deb M; Trebst C; Hemmer B; Stangel M; Windhagen A
    Mult Scler; 2008 Mar; 14(2):166-76. PubMed ID: 17942524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The comparative study of efficacy and tolerability of intramuscular introduction of beta-interferon-1a in adults and adolescents with remitting multiple sclerosis].
    Boĭko AN; Batysheva TT; Bykova OV; Davydovskaia MV; Demina TL; Lashch NIu; Nankina IA; Ovcharov VV; Popova EV; Popova NF; Boĭko OV; Khachanova NV; Shchur SG; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(2 Pt 2):98-103. PubMed ID: 22677685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy.
    Lanzillo R; Orefice G; Quarantelli M; Rinaldi C; Prinster A; Ventrella G; Spitaleri D; Lus G; Vacca G; Carotenuto B; Salvatore E; Brunetti A; Tedeschi G; Brescia Morra V
    Mult Scler; 2010 Apr; 16(4):450-4. PubMed ID: 20150398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon beta 1a-induced severe autoimmune hepatitis in patients with multiple sclerosis: report of two cases and review of the literature.
    Villamil A; Mullen E; Casciato P; Gadano A
    Ann Hepatol; 2015; 14(2):273-80. PubMed ID: 25671839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis.
    Wenzel J; Schmidt R; Proelss J; Zahn S; Bieber T; Tüting T
    Clin Exp Dermatol; 2006 Jul; 31(4):576-82. PubMed ID: 16716166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Safety and tolerability in the early phase of slow schedule versus fast schedule treatment with 44 micrograms of interferon beta-1a in patients with multiple sclerosis (PARALEN study)].
    Hernandez-Perez MA;
    Rev Neurol; 2009 May 16-31; 48(10):505-8. PubMed ID: 19434583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon β in dermatomyositis.
    Huard C; Gullà SV; Bennett DV; Coyle AJ; Vleugels RA; Greenberg SA
    Br J Dermatol; 2017 May; 176(5):1224-1230. PubMed ID: 27564228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy.
    Singh MK; Scott TF; LaFramboise WA; Hu FZ; Post JC; Ehrlich GD
    J Neurol Sci; 2007 Jul; 258(1-2):52-9. PubMed ID: 17467740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefit-risk assessment of interferon-beta therapy for relapsing multiple sclerosis.
    Francis G
    Expert Opin Drug Saf; 2004 Jul; 3(4):289-303. PubMed ID: 15268647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PRISMS: the story of a pivotal clinical trial series in multiple sclerosis.
    Cohen BA; Rivera VM
    Curr Med Res Opin; 2010 Apr; 26(4):827-38. PubMed ID: 20121658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study.
    Gold R; Rieckmann P; Chang P; Abdalla J;
    Eur J Neurol; 2005 Aug; 12(8):649-56. PubMed ID: 16053475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.
    Barbero P; Verdun E; Bergui M; Pipieri A; Clerico M; Cucci A; Ricci A; Bergamasco B; Durelli L
    J Neurol Sci; 2004 Jul; 222(1-2):13-9. PubMed ID: 15240190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression.
    Reder AT; Velichko S; Yamaguchi KD; Hamamcioglu K; Ku K; Beekman J; Wagner TC; Perez HD; Salamon H; Croze E
    J Interferon Cytokine Res; 2008 May; 28(5):317-31. PubMed ID: 18547162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.